Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 2/20 | 1.00 |
| ▸ | LIG3 | P49916 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 12/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.61 |
| ▸ | MEN1 | O00255 | 9/20 | 0.61 |
| ▸ | HTT | P42858 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401789 | 1.00 | LIG1 (1.00) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL19334306 | 0.91 | LIG1 (0.83) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL14959162 | 0.87 | LIG1 (0.78) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL13401821 | 0.86 | LIG1 (0.75) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL19334492 | 0.77 | LIG1 (0.62) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL17080648 | 0.76 | KDM4E (0.70) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL15457450 | 0.75 | MEN1 (0.77) | MAPTKDM4EKMT2AMEN1HTT | |
| SCHEMBL13401495 | 0.73 | LIG1 (0.58) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL13745514 | 0.73 | MAPT (0.67) | LIG1LIG3MAPTKDM4EKMT2A | |
| SCHEMBL13401793 | 0.73 | MEN1 (0.67) | LIG1LIG3MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11359200-B2 | Cancer treatment by MALAT1 inhibition | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210102212-A1 | CANCER TREATMENT BY MALAT1 INHIBITION | THE CLEVELAND CLINIC FOUNDATION | 2021-04-08 | — | — | US | disclosed |
| US-20170247703-A1 | ANTIVIRAL NUCLEASE METHODS | AGENOVIR CORPORATION | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11359200-B2 | Cancer treatment by MALAT1 inhibition | MAL2, HNRNPH3, RNASE1 | LIG1 492/4885LIG3 308/4885MAPT 1631/4885 |
| US-20210102212-A1 | CANCER TREATMENT BY MALAT1 INHIBITION | MAL2, HNRNPH3, RNASE1 | LIG1 492/4885LIG3 308/4885MAPT 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.